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One can be stigmatized by society for having been diagnosed by genetic analysis 
with a particular disease and then denied health and life insurance when the person 
at that moment is perfectly capable and without a serious medical condition. 
Furthermore, decisions regarding prenatal diagnosis to abort because the unborn 
has been tested positive for a genetic disease discriminate against their right to live. 
Prejudice, alienation and exclusion often accompany genetic associated diseases, 
even though persons have no control over a disorder that is not the result of willful 
behavior. 
1. The Human Genome Project and Genetic Discrimination 
The international effort of the human genome project, which seeks to map and 
sequence all of the estimated 3 billion bp that make up the human genome, is 
expected to provide information in the near future of the thousands of mutations 
that are responsible for inherited diseases, thus making possible highly accurate 
diagnoses. The project will provide a better understanding both of single gene 
defects and multifactorial or familial diseases, such as diabetes and cancer. 
While for some researchers the genome mapping project is essentially an 
engineering-morally neutral-problem, many other scientists recognize the 
potential ethical and sociological problems that the acquisition of the new genetic 
knowledge will generate. One ethical issue for consideration is the possibility of 
discrimination. The employer, insurer and state may have an interest in having 
access to information from genetic tests performed on individuals with the risk of 
potential genetic discrimination, such as non-equal access to work, high insurance 
fees and pressure to opt for sterilization in cases of carriers of genetic diseases or 
pregnancy termination in cases of embryos or fetuses with genetic mutations for 
diseases. 
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About 3,000 different human diseases have been shown to result from 
hereditary defects on a single altered gene, and many genes may play an indirect 
role in disease. l Almost 40,000 recognized disorders with a genetic component 
have been recorded.2 Some are polygenic or multifactorial, involving the 
inheritance of several genes; others are monogenic, involving one gene only; others 
are chromosomal, involving chromosomal aberrations; many diseases result from 
the interaction of genes and the environment. Genetic diseases and congenital 
malformations occur approximately in 3-5% of all live births. It is expected that 
with the information generated by the human genome project, medical genetics 
will permeate almost every aspect of medical research and clinical practice. The 
number of genetic tests is expected to increase every year as a result of the 
information gained from the project. Genetic tests detect the mutations (changes in 
the genetic material) that cause the disease at the chromosomal and gene level. 
Genetic Tests and Discrimination 
In applying genetic tests there are complications which increase the possibility 
of discrimination due to misunderstandings of the implications of test results. 
Some of these are: 
(I) Some genetic tests make possible the diagnosis of a disease before the 
symptoms are produced (presymptomatic diagnosis). Predictive diagnosis for late 
onset diseases, such as Huntington disease, is becoming increasingly possible. In 
this type of disease the person can live free of its effects during most oflife. (2) Even 
when the genetic defect is present, some diseases may never be fully expressed; for 
example, 20 percent of persons who carry the gene for fragile-X, the most 
common form of mental retardation, never express any form of mental 
retardation. (3) Though genetic tests for susceptibility to certain diseases, such as 
for coronary heart disease and cancer, will be developed, these can only provide 
probabilistic information whether an increased risk exists. (4) Errors in the 
diagnosis depending on the disease, the type of mutation, and the test employed 
may also occur. Indeed, differentiation between harmless polymorphic alterations 
and disease-causing mutations is difficult without the additional work of 
sequencing, which is not always feasible. In the case of a test for detecting a 
polymorphism in a nearby region of the mutated gene, which is inherited with the 
disease, there is the chance, although slight, of genetic recombination which yields 
false results. (5) For many of the diseases there is genetic heterogeneity so that 
more than one mutation and/or gene are involved; particularly X-linked diseases 
are prone to newly arising mutations so that almost every affected family displays a 
different alteration. Testing for the large number of mutations that may be 
involved is usually not feasible and it can lead to misdiagnosis if the particular 
mutation causing the disease is not covered by the test. (6) Even with the same 
mutations in some cases (susceptibility-conferring mutation) there are markedly 
variable clinical expressions depending on environmental factors and modifying 
genes that interact with the mutated gene. (7) Even when a particular disease can 
be diagnosed, in many cases there is no cure for it. (8) The process of explaining 
genetic risks is complex and easily misunderstood by people without a background 
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in genetics. Genetic counselors and doctors and nurses with adequate background 
in genetics are necessary. (9) It will take time until a consensus is reached by the 
medical community about which genetic tests have sufficient predictive value for 
specific diseases.3 
With the new information generated by the genome project the probability of 
finding mutant genes is going to be greatly magnified, so that the possibilities of 
being stigmatized will be much greater. 
3. Genetic Discrimination and Health Insurance 
One potential risk of genetic discrimination, based on the acquisition of 
information through genetic tests, is in relation to the insurance industry. Insurance 
companies can discriminate by denying life, health or disability insurance to 
people on the basis of their genotypes. The current health-care system in the 
United States focuses on treatment rather than on prevention. For that reason, the 
predictive value of genetic tests is of little positive value for insurance companies. 
But, health insurance companies, in order to keep their prices down and to be 
competitive with other companies, may refuse to insure people who are at risk of 
having high medical expenses. As a result, some people cannot afford insurance 
because they are already ill or are at risk of illness. Through the principles of 
underwriting, insurers estimate the chances that an applicant will make a claim. 
The notion of "actuarial fairness" plays a key role in this estimation. By means of it, 
parties seeking insurance ought to pay according to their potential risks for filing a 
claim. Many insurance companies require physical examinations which 
sometimes reveal genetic disorders, and ask questions of the applicants which may 
elicit information about their genetic background. Applicants are also asked to 
permit release of medical information from doctors who previously have treated 
them. There are no safeguards to prevent insurance companies from exchanging 
stigmatizing information with employers during the claim process. During 
underwriting, physicians commonly release genetic information to insurers.4 
At present it appears that insurance companies do not require molecular genetic 
tests in underwriting or in the process of establishing premiums according to the 
risk of developing diseases. Still, insurers make decisions based on genetic 
information, including family history or prior diagnostic tests performed on the 
client or his/her family. Many companies require policyholders to sign releases 
that allow access to any and all records. Currently most genetic information 
available is too costly to be used as a routine insurance screen. However, with 
technological advances it is expected that genetic testing will be included in 
insurance underwriting in the near future by using cost-effective multiple tests. The 
common, severe and costly diseases are most likely to attract insurers' interest once 
the predictive value of a genetic test is confirmed and the word spreads among 
insurers. Biotechnology firms are interested in developing diagnostic tests for 
genetic disorders and one potential market for the use of these tests is the insurance 
industry.5 Insurers insist that they must not be prevented from using data on 
genetic-testing already collected in the medical record to assess risk of candidates 
for initial coverage in order to protect the companies and other policyholders from 
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the results of adverse selection.6 
Adverse selection consists in the tendency of people who learn they have higher 
risks of disease to purchase insurance. This occurs when individuals have more 
information about their risk of illness than do insurance companies. Adverse 
selection poses a greater problem to insurance companies for life and disability 
insurance since these forms of insurance are obtained through individual 
applications. Insurance companies claim that adverse selection will jeopardize 
their interests and for that reason they are developing strategies to protect 
themselves. Because of competition among insurance companies, the tendency 
will be towards screening for predisposition. If one insurance company begins to 
use genetic tests and is able to offer lower rates to individuals who are not 
predisposed to disease and higher rates to individuals who have predisposition to 
disease, this particular insurance company would draw people who are offered 
low rates and this will put pressure on other insurance companies to also offer 
genetic tests. In this way insurers can assess the risk of candidates for initial 
coverage, their renewal or increased coverage or decide not to cover certain 
indi viduals. 7 
On the other hand, the health insurance industry has been criticized for 
practicing "adverse selection," for example, by discontinuing coverage when a 
client, who has been faithfully paying premiums, is found to have a serious 
condition.s The proliferation of new genetic tests heightens the concern that 
insurance companies, requiring applicants to provide blood samples, may perform 
genetic tests on them without making the results known to the clients.9 In the 
absence of a cure for most genetic diseases, insurers will be reluctant to insure 
people at risk of developing costly disorders. This issue provides a high potential 
for discriminatory practices. 
4. Genetic Discrimination and Abortion 
Genetic discrimination may result in the abortion of an individual who tests 
positive for a genetic disease by prenatal diagnosis, although every human being 
-including fetuses - has the right to receive adequate medical attention if needed. 
The possibility that insurance companies will refuse in the future to insure 
individuals who, as fetuses are shown to have a genetically inherited disease, will 
put pressure on families to abort because of economical constraints. Furthermore, 
if abortion of genetically defective embryos or fetuses becomes widespread, there 
is the danger of reinforcing negative attitudes in society against people born with 
disabilities. Theoretically, for single gene disorders for which there is no present 
cure, to try to develop gene therapy constitutes an alternative.ln reality, however, 
the impetus for developing this therapy is blunted by the use of gene probes and 
other diagnostic technologies to detect and abort affected fetuses and to counsel 
at-risk adults against procreation. Furthermore, the practice of embryo selection in 
in vitro fertilization procedures is as well discriminatory, since the embryos not 
selected are very rarely given the chance to develop. 
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5. Ethical Reflection 
I consider that ethical reflection needs a proper definition of personhood on 
which to base moral decisions. For example, moral decisions with respect to the 
implementation of genetic knowledge depend on the value given to the person as a 
whole. In a society where there is confusion over what it means to be a person, 
there is also a confusion over what is moral. It is then necessary to consider the 
definition of personhood in accordance with the dignity due to a human being. 
Genesis (1 :26) gives a transcendental meaning of what a human being is, revealing 
that he/she is "image and likeness" of the Divine being. Through the motif of the 
image of God (cf. Ps 8:5; Wis 2:23; 1 Cor 11 :7) the Bible affirms the sacredness and 
dignity of every human person. According to Gula this statement contains the 
theological meaning that God has established a relationship with human persons 
which is sustained by divine faithfulness and 10ve.1O The statement also contains 
the anthropological meaning that we all share a common human condition with 
God as common end, and that human dignity does not depend on human 
achievements alone, but on divine love as well. For the contemporary philosopher 
Fernando Rielo this statement implies that the Divine being is forming 
ontologically the human being. II Personhood cannot be defined by something 
inferior to itself. To assert this would be to reduce the person to a property, such as 
intellectual capacity, independence, etc. Rather, personhood should be defined by 
a term, the Absolute being, that transcends and encompasses all these 
characteristics. The essence of the human person is to be a being in relation to God, 
thereby to other human beings and to the whole of nature. This definition renders 
morally prohibitive any action that would in any way compromise the proper 
realization of this relationship. Faith helps Christians to see the dignity of a human 
being against cultural pressures that distort it. The capacity of the human being to 
establish human rights and the ethical obligation to carry them out confirms that 
the person cannot be reduced to a naive or moderate materialism. 
The Magisterium has consistently taught the dignity of human beings and the 
inviolability of human life. Human dignity, rooted in the Bible, arises from three 
sources: creation in the image of God (Gen. 1 :26), redemption, achieved through 
the incarnation, death and resurrection of Jesus Christ (In 3:16; Eph 1:10; 1 Tim 
2:4-6), and our common destiny to share a life with God beyond all corruption (I 
Cor 15:42-57; I Jn 3:1-2).12 When the Magisterium asserts that human life is 
sacred, given that from the beginnings it involves "the creative action of God and it 
remains forever in a special relationship with the Creator, who is its sole end,"J3 
and that "the spiritual soul of each man is immediately created by God",14 it is 
arguing that there is no separation between the spiritual dimension of the person 
and the individual's physical life, since both are present from the beginning. 
Human life therefore is sacred; it has been touched by God and deserves the highest 
respect from the moment of conception. 
Morally every individual should be given the highest value regardless of race, 
ethnicity, social condition, age, sex, stage of embryonic or fetal development, 
religion or physical health. All human beings deserve respect and protection and 
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promotion of their basic rights because of their dignity. The value of a person 
cannot be measured by his/her genetic constitution. Knowledge of the genetic 
cause of diseases has as its final objective the cure or prevention of the disease, not 
the elimination or discrimination of the individuals that possess genetic mutations. 
Virtually all human beings possess one or another genetic mutation. The fact that 
one has mutations does not necessarily mean that this is an evil. Part of the function 
of mutations is an evolutionary strategy to provide a reservoir for adapting to 
changing environmental circumstances. Performing genetic testing for the purpose 
of eliminating the individuals that do not test normal is clearly immoral. Choosing 
embryos with a particular genotype in in vitro fertilization procedures is immoral 
because it implies making a judgment regarding which embryo deserves to be 
developed and which one does not; ultimately this is a value judgment concerning 
who has the right to live and who does not. The embryos which are not destined to 
grow must be frozen, destroyed or used for research, which clearly violates human 
dignity. 
Performing genetic tests with the purpose of identifying individuals who do not 
test normal and then denying them insurance or other basic values is immoral 
because it violates the right to receive health benefits. This goes against justice. I 
consider that the practice of establishing premiums based on risk by insurers is 
unj ust and therefore a better system must be found. The notion of actuarial fairness 
does not coincide with moral fairness. The expenses of health care should be 
shared by all equally with the establishment of adequate social policies. It is not 
right that because somebody has been born with a genetic disease, he/she has to 
pay more. This puts pressure on families to avoid having a defective child and 
leaves society with the impression that it is better not to care for those who have 
abnormalities. We are here in life to help others, not to put further difficulties on 
those who have been born with health problems. The present health care system in 
the US does not promote equal opportunity since access to health care depends, for 
the most part, on the ability to pay. The health care system should reject the 
possibility that individuals can have economic advantage from differences in their 
health risk. On the other hand, enhancement services, such as "cosmetic surgery," 
could be excluded from coverage on the ground that it does not constitute a 
treatment of disease and there is no social obligation for it. 
Conclusion 
Maximum respect for human dignity should be the guiding principle in all 
ethical decisions. If the person is an "image" of God, then maximum respect and 
treatment should be given to the person, without discrimination, regardless of race, 
ethnicity, genetic constitution or stage of development. Laws that permit abortion 
or active euthanasia go against human dignity. Health is not an absolute end, but a 
subordinate goal; thus it is not the case that if you are not going to be healthy, it is 
better that you do not live; rather, health is a means for improving the quality oflife 
for which we strive. It is necessary to emphasize the value and the importance of 
every human being. 
A reform in the health care system in this country could prevent the possibility 
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of genetic discrimination by insurance companies by assuring access to care for 
everyone. At present the law does not seem to prevent insurers from exercising 
genetic discrimination. The general applicability of genetic tests may force the 
situation in the direction of socialized medicine, which will be more effective in 
handling the problem. This is critical for cases of (1) presymptomatic diagnosis in 
which the patient is at risk of having high insurance premiums in the present 
system instead of receiving preventive care, and (2) for prenatal diagnosis of 
diseases for which there is no cure. 
Abortion for fetal indications is immoral because it involves the end of a life, 
when life constitutes a higher value than the suffering a human being will have to 
undergo if genetically injured. Society has the duty to try to provide the best 
environment possible to diminish the suffering of individuals born with diseases. If 
there are no institutions that care and help individuals with genetic diseases, all the 
burden falls on family members who are pressured to avoid the birth of these 
individuals. Hence the development of needed services and institutions is clearly a 
societal responsibility. 
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